Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Efficacy and Safety of Tenecteplase in Wake-up Stroke Patients by Non-contrast CT (TWIST)

admin by admin
February 14, 2023
in News


The following is a summary of the “Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomized controlled trial,” published in the February 2023 issue of Neurology by Roaldsen, et al.


Clinical guidelines and current evidence both advocate intravenous thrombolysis with alteplase for patients with wake-up stroke who have been identified for treatment using magnetic resonance imaging or perfusion imaging. However, there is typically a lack of availability for high-tech imaging methods. Researchers wanted to ascertain if the functional outcome is improved in patients with ischemic wake-up stroke chosen by non-contrast CT if thrombolytic treatment with intravenous tenecteplase is administered within 4–5 h of awakening. The TWIST study involved 77 hospitals in 10 countries and was an investigator-initiated multicenter open-label randomized controlled experiment with blinded endpoint assessment. Patients were eligible if they were 18 or older, woke up with symptoms of acute ischaemic stroke, such as limb weakness, a National Institutes of Health Stroke Scale (NIHSS) score of 3 or higher, or aphasia, had a non-contrast CT of the head, and could receive tenecteplase within 4–5 hours of awakening.  Patients were allocated to receive either a single intravenous bolus of tenecteplase 0.25 mg per kg of body weight (maximum 25 mg) or control (no thrombolysis) based on a central, web-based, computer-generated randomization schedule (1:1). 

Research assistants were blinded to participants’ treatment assignments when they called them 90 days later to perform follow-up interviews. Upon admission to the hospital, clinical evaluations were conducted on Day 1 (for baseline purposes) and on Day 7 (or at discharge, whichever occurred first). In the study’s primary analysis, the 90-day functional outcome on the modified Rankin Scale (mRS) was analyzed with intention-to-treat population ordinal logistic regression. About 578 out of the required 600 individuals were enrolled between June 12, 2017, and September 30, 2021. (288 randomly assigned to the tenecteplase group and 290 to the control group [intention-to-treat population]). Participants’ median ages ranged from 737 to 811. Out of the total of 578 people, 332 (57%) were male and 246 (43%) were female. 

According to the modified Rankin Scale (mRS) at 90 days, tenecteplase treatment was not related with better functional outcome. (Adjusted OR = 1.18; 95% CI = 0.88-1.58; p = 0.27). There was no statistically significant difference in the 90-day mortality rate between the tenecteplase and control groups (28 patients (10%) in the tenecteplase group and 23 patients (8%) in the control group; adjusted HR 1.29, 95% CI 0.74-2.26; P=0.37). About 6 patients in the tenecteplase group (2%) and 3 patients in the control group (1%) experienced symptomatic intracranial haemorrhage (adjusted OR 217, 95% CI 053-887; P=028), while 33 patients in the tenecteplase group (11%) and 30 patients in the control group (10%) experienced any intracranial haemorrhage (adjusted OR 114). Treatment with tenecteplase was not related with improved functional outcome at 90 days in patients with wake-up stroke who were chosen using non-contrast CT. Previous trials of wake-up stroke patients screened with sophisticated imaging have shown that the number of symptomatic haemorrhages and any intracranial haemorrhages in both therapy groups is comparable. Patients identified using non-contrast CT do not currently have sufficient evidence to warrant treatment with tenecteplase.

Source: sciencedirect.com/science/article/abs/pii/S1474442222004847



Source link

Advertisement Banner
Previous Post

Signs, Symptoms, and Treatment of Aspiration Pneumonia

Next Post

Give Him a Hand – No, Really – The Health Care Blog

Related Posts

News

Insights from Normalization Process Theory

March 23, 2023
News

Transdermal Testosterone Pretreatment Improves Live Birth Rates in Poor Responders

March 22, 2023
News

Ph-positive Acute Lymphoblastic Leukaemia Treated with Ponatinib and Blinatumomab

March 21, 2023
News

High-Risk Hodgkin Lymphoma and BV+Nivolumab After HSCT

March 20, 2023
News

History of Adverse Pregnancy Outcomes Linked to Coronary Artery Disease

March 19, 2023
News

American College of Cardiology, March 4 to 6

March 18, 2023
Next Post

Give Him a Hand – No, Really – The Health Care Blog

Recommended

HJ23 session: Putting a face on family caregiving

1 week ago

What Does the TID Medical Abbreviation Mean?

4 months ago

Should mRNA vaccine myocarditis be a contraindication to future COVID-19 vaccinations ? – The Health Care Blog

2 months ago

Half of Frontline Health Care Workers Report Subthreshold PTSD Symptoms

1 month ago

Airway Management for Patients Suffering Cardiac Emergencies

2 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.